UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | E | G | H | J | K | L | M | N | O | P | R | S | T | V | W
Number of items: 160.

A

Abell, K; Bilancio, A; Clarkson, RW; Tiffen, PG; Altaparmakov, AI; Burdon, TG; ... Watson, CJ; + view all (2005) Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol , 7 (4) 392 - 398. 10.1038/ncb1242.

Ah- See, ML; Burcombe, RJ; Daley, FM; Richman, P; Padhani, AR; Bentzen, SM; ... Makris, A; + view all (2005) Evaluation of tunour microvessel density and pericyte coverge index following neoadjuvant chemotherapy in primary breast cancer. In: Proceedings of of ASCO. (pp. 42s - 42s).

Ah-See, M; Makris, A; Taylor, NJ; Stirling, JJ; Daley, FM; Richman, P; ... Padhani, AR; + view all (2005) Correlating breast cancer and hypoxia status with MRI features. In: Breast Cancer Research and Treatment. (pp. S205 - ?).

Ah-See, M; Padhani, AR; Taylor, NJ; Harris, AL; Burcombe, RJ; Fox, SB; ... Makris, M; + view all (2005) Lack of correlation between microvessel density & pericyte coverage index with breast cancer biposies & functional dynamic contrast-enhanced MRI-derived vascular parameters. In: Breast Cancer Research and Treatment. (pp. S74 - S75).

Ah-See, MW; Harris, AL; Burcombe, RJ; Fox, SB; Richman, PI; Daley, FM; ... Makris, A; + view all (2005) Evaluation of the effects of neoadjuvant chemotherapy on tumour microvessel density(MVD), pericyte coverage index(PCI), & vascular enodthelial growth factor(VEGF)in primary breast cancer. In: Breast Cancer Research and Treatment. (pp. S224 - ?).

Alonzi, R; Hoskin, P; (2005) Novel therapies in bladder cancer. CLINICAL ONCOLOGY , 17 (7) 524 - 538.

Andy, S; (2005) My dad’s fight with lung cancer. Daily Express 30 - 31.

Ardeshna, KM; Kakouros, N; Qian, W; Powell, MG; Saini, N; D'Sa, S; ... Linch, DC; + view all (2005) Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. BRITISH JOURNAL OF HAEMATOLOGY , 130 (3) 363 - 372.

Arkenau, H; Kubicka, S; Greil, R; Schmoll, H; Seufferlein, T; Greaven, U; ... Porschen, R; + view all (2005) Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis. EJC SUPPL , 3 (2) 168 - 168.

Arkenau, H; Porschen, R; (2005) Adjuvante Therapie des Kolonkarzinoms. In: Schoelmerich, J and Schmiegel, W, (eds.) Leitfaden Kolorektales Karzinom. (175 - 183). Uni-Med.-Verlag: Bremen, Germany.

Arkenau, HT; Müssig, O; Buhr, T; Jend, HH; Porschen, R; (2005) Microangiopathic hemolytic anemia (MAHA) as paraneoplastic syndrome in metastasized signet ring cell carcinomas: case reports and review of the literature. Z Gastroenterol , 43 (8) 719 - 722. 10.1055/s-2005-858259.

Arkenau, HT; Rettig, K; Porschen, R; (2005) Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis , 20 (3) 258 - 261. 10.1007/s00384-004-0657-6.

Attard, G; Plummer, RE; De Bono, JS; Bale, C; Fong, P; Barrett, M; ... Calvert, H; + view all (2005) Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies. In: CLINICAL CANCER RESEARCH. (pp. 9060S - 9060S). AMER ASSOC CANCER RESEARCH

Azzabi, A; Hughes, AN; Calvert, PM; Plummer, ER; Todd, R; Griffin, MJ; ... Boddy, AV; + view all (2005) Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. BRIT J CANCER , 92 (6) 1006 - 1012. 10.1038/sj.bjc.6602438.

B

Barber, LJ; Ward, TA; Hartley, JA; McHugh, PJ; (2005) DNA interstrand cross-link repair in the Saccharomyces cerevisiae cell cycle: Overlapping roles for PSO2 (SNM1) with MutS factors and EXO1 during S phase. MOL CELL BIOL , 25 (6) 2297 - 2309. 10.1128/MCB.25.6.2297-2309.2005. Gold open access

BBC, NB; (2005) Lung cancer scientist dies at 92. UNSPECIFIED

BBC, NO; (2005) 'Freeze therapy' for lung cancers. UNSPECIFIED

BBC, NO; (2005) Thalidomide slows cancer disease. UNSPECIFIED

BBC, NO; (2005) Warning to heed lung cancer signs. UNSPECIFIED

Begent, RHJ; Kerr, P; Parkinson, H; Reddington, F; Wilkinson, JM; (2005) NCRI Informatics initiative. UNSPECIFIED

Bentzen, SM; Atasoy, BM; Daley, FM; Dische, S; Richman, PI; Saunders, MI; ... Wilson, GD; + view all (2005) Epidermal growth factor receptor expression in pre-treatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomised controlled trial. Journal of Clinical Oncology , 23 (24) 5560 - 5567. 10.1200/jco.2005.06.411.

Beresford, M; Ah-See M L, T; N J, S; J J, M; A, DJA; Leach, MO; Padhani, AR; (2005) Inter-and intra-observer variability of DCE-MRI in breast cancer. In: Proceedings of the International Society of Magnetic Resonance Medicine.

Beresford, M; Glynne-Jones, R; Richman, P; Makris, A; Mawdsley, S; Stott, D; ... Harrison, RA; + view all (2005) The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy. CLINICAL ONCOLOGY , 17 (6) 448 - 455.

Beresford, M; Padhani, AR; Goh, V; Makris, A; (2005) Imaging breast cancer response during neoadjuvant systemic therapy. Expert Review of Anticancer Therapy , 5 (5) 893 - 905.

Beresford, MJ; Ah-See, M; Daley, F; Richman, P; Harris, A; Makris, A; (2005) The role of the angiogenic marker, endoglin, as a predictor of response to neoadjuvant chemotherapy in primary bresat cancer. In: Breast Cancer Research and Treatment. (pp. S59 - S59).

Beresford, MJ; Ah-See, ML; Burcombe, R; Dixon, J; Ostler, P; Harrsion, M; ... A,; + view all (2005) Do pre-treatment haemaglobin levels predicct for response to neoadjuvant chemotherapy in breast cancer? In: Proc of ASCO. (pp. 80s - 80).

Beresford, MJ; Makris, A; Taylor, NJ; Stirling, JJ; Ah-See, M; d'Arcy, JA; ... Padhani, AR; + view all (2005) Observer variability in dynamic contrast-enhanced MRI when used for prediction of response to neoadjuvant chemotherapy in primary breast cancer. In: Breast Cancer Research and Treatment. (pp. S206 - ?).

Birtle, AJ; Freeman, A; Masters, JRW; Payne, HA; Harland, SJ; Baus Section Oncology Canc Registr,; (2005) Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < 10 ng/mL. BJU INT , 96 (3) 303 - 307. 10.1111/j.1464-410X.2005.05619.x.

Boddy, AV; Plummer, ER; Todd, R; Sludden, J; Griffin, M; Robson, L; ... Calvert, AH; + view all (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. CLIN CANCER RES , 11 (21) 7834 - 7840. 10.1158/1078-0432.CCR-05-0803.

Boxer, GM; Tsiompanou, E; Levine, T; Watson, R; Begent, RHJ; (2005) Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer. TUMOR BIOL , 26 (1) 1 - 8. 10.1159/000084180.

Braybrooke, JP; Slade, A; Deplanque, G; Harrop, R; Madhusudan, S; Forster, MD; ... Harris, AL; + view all (2005) Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res , 11 (4) 1512 - 1520. 10.1158/1078-0432.CCR-04-0155.

Brooks, S; Bownes, P; Lowe, G; Bryant, L; Hoskin, PJ; (2005) Cervical brachytherapy utilizing ring applicator: comparison of standard and conformal loading. International Journal of Radiation Oncology Biology Physics , 63 (3) 934 - 939.

Buchmueller, KL; Taherbhai, Z; Howard, CM; Bailey, SL; Nguyen, B; O'Hare, C; ... Lee, M; + view all (2005) Design of a hairpin polyamide, ZT65B, for targeting the inverted CCAAT box (ICB) site in the multildrug resistant (MDR1) gene. CHEMBIOCHEM , 6 (12) 2305 - 2311. 10.1002/cbic.200500179.

Burcombe, RJ; Makris, A; Richman, PI; Daley, FM; Noble, S; Pittam, M; ... Wilson, GD; + view all (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. British Journal of Cancer , 92 (1) 147 - 155.

Burton, C; Smith, P; Vaughan-Hudson, G; Qian, W; Hoskin, P; Cunningham, D; ... Linch, D; + view all (2005) Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY , 130 (4) 536 - 541.

C

Calvert, AH; (2005) Fishing for new drugs. J CLIN ONCOL , 23 (31) 7780 - 7782. 10.1200/JCO.2005.08.004.

Calvert, H; Twelves, C; Ranson, M; Anthoney, A; Plummer, R; Fettner, S; ... Rakhit, A; + view all (2005) The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 210S - 210S). AMER SOC CLINICAL ONCOLOGY

Capponcelli, S; Pedrini, E; Cerone, MA; Corti, V; Fontanesi, S; Alessio, M; ... Sangiorgi, L; + view all (2005) Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. Hum Mutat , 26 (2) 94 - 103. 10.1002/humu.20192.

Casely-Hayford, MA; Pors, K; James, CH; Patterson, LH; Hartley, JA; Searcey, M; (2005) Design and synthesis of a DNA-crosslinking azinomycin analogue. ORG BIOMOL CHEM , 3 (19) 3585 - 3589. 10.1039/b508908e.

Cerone, MA; Autexier, C; Londoño-Vallejo, JA; Bacchetti, S; (2005) A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene , 24 (53) 7893 - 7901. 10.1038/sj.onc.1208934.

Cerone, MA; Ward, RJ; Londoño-Vallejo, JA; Autexier, C; (2005) Telomerase RNA mutated in autosomal dyskeratosis congenita reconstitutes a weakly active telomerase enzyme defective in telomere elongation. Cell Cycle , 4 (4) 585 - 589.

Chang, JC; Hisenback, SG; Yee, D; Tsimelzon, A; Harrison, M; Gutierrez, CM; ... A,; + view all (2005) Gene expression profiles as predictors of response to neoadjuvant taxotere and adriamycin/cyroxan:a propsective randomized trial in breast cancers. In: Breast Cancer Research Treatment. (pp. S31 - S31).

Chester, KA; Baker, M; Mayer, A; (2005) Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol , 1 (4) 549 - 559. 10.1586/1744666X.1.4.549.

Cheung, CW; Burton, C; Smith, P; Linch, DC; Hoskin, PJ; Ardeshna, KM; (2005) Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. BRIT J HAEMATOL , 131 (2) 193 - 200. 10.1111/j.1365-2141.2005.05756.x.

Cleator, SJ; Makris, A; Ashley, SE; Lal, R; Powles, TJ; (2005) Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Annals of Oncology , 16 (2) 267 - 272.

Clingen, PH; De Silva, IU; McHugh, PJ; Ghadessy, FJ; Tilby, MJ; Thurston, DE; Hartley, JA; (2005) The XPF-ERCC1 endonuclease and homologous recon bination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. NUCLEIC ACIDS RES , 33 (10) 3283 - 3291. 10.1093/nar/gki639. Gold open access

Condliffe, AM; Davidson, K; Anderson, KE; Ellson, CD; Crabbe, T; Okkenhaug, K; ... Hawkins, PT; + view all (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. BLOOD , 106 (4) 1432 - 1440. 10.1182/blood-2005-03-0944.

Corrie, PG; Shaw, J; Spanswick, VJ; Sehmbi, R; Jonson, A; Mayer, A; ... Cree, IA; + view all (2005) Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. BRIT J CANCER , 92 (11) 1997 - 2003. 10.1038/sj.bjc.6602586.

Corrie, PG; Shaw, J; Spanswick, VJ; Sehmbi, R; Jonson, A; Mayer, A; ... Cree, IA; + view all (2005) Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. British Journal of Cancer , 92 (11) 1997 - 2003.

Cutillas, PR; Geering, B; Waterfield, MD; Vanhaesebroeck, B; (2005) Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol Cell Proteomics , 4 (8) 1038 - 1051. 10.1074/mcp.M500078-MCP200.

D

Daniell, K; Stewart, M; Madsen, E; Le, M; Handl, H; Brooks, N; ... Lee, M; + view all (2005) Design, synthesis, and biological evaluation of achiral analogs of duocarmycin SA. BIOORG MED CHEM LETT , 15 (1) 177 - 180. 10.1016/j.bmcl.2004.10.021.

Daniell, K; Stewart, M; Madsen, E; Le, M; Handl, H; Brooks, N; ... Lee, M; + view all (2005) Design, synthesis, and biological evaluation of achiral analogs of duocarmycin SA. Bioorg Med Chem Lett , 15 (1) 177 - 180. 10.1016/j.bmcl.2004.10.021.

Dark, GG; Calvert, AH; Grimshaw, R; Poole, C; Swenerton, K; Kaye, S; ... Eisenhauer, EA; + view all (2005) Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group. JOURNAL OF CLINICAL ONCOLOGY , 23 (9) 1859 - 1866. 10.1200/JCO.2005.02.028.

de Bruin, EC; van de Pas, S; Lips, EH; van Eijk, R; van der Zee, MM; Lombaerts, M; ... Peltenburg, LT; + view all (2005) Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics , 6 142 - ?. 10.1186/1471-2164-6-142.

Dearling, JLJ; Flynn, AA; Beken, L; Petrie, IA; El-Emir, E; Boxer, GM; ... Pedley, RB; + view all (2005) Dose Estimation in a 3D Tumour Reconstruction -Impact of the Heterogeneity of TumourPathophysiology on RIT and EBRT. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. (pp. S83 - S83).

Dearling, JLJ; Qureshi, U; Begent, RHJ; Pedley, RB; (2005) Radioimmunotherapy Combined with Anti-Hypoxia Therapy 2DG Results in Reduction of Therapeutic Efficacy. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. (pp. S48 - S48).

Dearling, JLJ; Qureshi, U; Begent, RHJAPRB; (2005) RIT given in combination with anti-hypoxia therapy 2DG leads to loss of therapeutic efficacy. In: (Proceedings) NCRI cancer Conference Proceedings. (pp. 66 - ?).

Dearling, JLJ; Qureshi, U; Whiting, S; Boxer, G; Begent, RHJAPRB; (2005) Quantitative autoradiography revelas higher antibody uptake in peripheral intrahepatic deposits than in central deposits. In: (Proceedings) NCRI Cancer Conference Proceedings. (pp. 56 - ?).

Dearling, JLJ; Qureshi, U; Whiting, S; Boxer, GM; Begent, RHJ; Pedley, RB; (2005) Analysis of Antibody Distribution Reveals Higher Uptake in Peripheral Intrahepatic Deposits Than Central Deposits. In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. (pp. S83 - S83).

Deborah, H; (2005) I haven’t smoked for 23 years yet now I face the serves-you-right stigma of this forgotten disease. Evening Standard 27 - 28.

E

El, EE; Dearling, J; Huhalov, A; Neri, D; Begent, RHJ; Pedley, RB; (2005) Targeting tumour vasculature in human colorectal xenografts using against the extra-domain B of fibronectin. In: (Proceedings) NCRI Cancer Conference proceedings.

El-Emir, E; Boxer, GM; Petrie, IA; Boden, RW; Dearling, JLJ; Begent, RHJ; Pedley, RB; (2005) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. EUR J CANCER , 41 (5) 799 - 806. 10.1016/j.ejca.2005.01.001.

G

Gibbs, DD; Theti, DS; Wood, N; Green, M; Raynaud, F; Valenti, M; ... Jackman, AL; + view all (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res , 65 (24) 11721 - 11728. 10.1158/0008-5472.CAN-05-2034.

Guest, RD; Hawkins, RE; Kirillova, N; Cheadle, EJ; Arnold, J; O'Neill, A; ... Gilham, DE; + view all (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens. J IMMUNOTHER , 28 (3) 203 - 211.

H

Hardcastle, IR; Ahmed, SU; Atkins, H; Calvert, AH; Curtin, NJ; Farnie, G; ... Lunec, J; + view all (2005) Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. BIOORG MED CHEM LETT , 15 (5) 1515 - 1520. 10.1016/j.bmcl.2004.12.061.

Hartley, JA; Hochhauser, D; Lee, M; Howard, PW; Thurston, DE; (2005) DNA targeting with PBD and polyamide-based agents. In: CLINICAL CANCER RESEARCH. (pp. 9176S - 9176S). AMER ASSOC CANCER RESEARCH

Hartmann, G; Vassileva, V; Piquette-Miller, M; (2005) Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. DRUG METAB DISPOS , 33 (6) 820 - 828. 10.1124/dmd.104.002568.

Henderson, SR; Guiliano, D; Presneau, N; McLean, S; Frow, R; Vujovic, S; ... Boshoff, C; + view all (2005) A molecular map of mesenchymal tumors. GENOME BIOL , 6 (9) , Article R76. 10.1186/gb-2005-6-9-r76. Green and gold open access
file

Ho, EA; Vassileva, V; Allen, C; Piquette-Miller, M; (2005) In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. J CONTROL RELEASE , 104 (1) 181 - 191. 10.1016/j.jconrel.2005.02.008.

Hoskin, PJ; (2005) Palliative radiotherapy for non-small-cell lung cancer: Which dose? ELSEVIER SCIENCE LONDON, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND

Hoskin, PJ; (2005) Radioisotopes for metastatic bone pain. LANCET LTD, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND

Hoskin, PJ; (2005) Evaluation and mangement of the patient with bone metastases at presentation. In: Claude, JE and Rodolfo, CE and Lawrence, CE and Robert, CE and Gerard, S, (eds.) Textbook of Bone Metastases. (545 - 554). John Wiley & Sons

Hoskin, PJ; (2005) Overview of treatment.Cancer Pain. In: Stephen, MMK, (ed.) Wall & Melzac's Textbook of Pain. Churchill Livingstone

Hoskin, PJ; Ahmedzai, S; Muers, MF; (2005) Assessment and management of respiratory symptoms of malignant disease. In: Ahmedzai, S and Muers, MF, (eds.) Supportive care in respiratory disease. (463 - 486). Oxford University Press

Hoskin, PJ; Rojas, AM; Phillips, H; Saunders, MI; (2005) Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. CANCER , 103 (11) 2287 - 2297. 10.1002/cncr.21048.

Hoskin, PJ; Smith, P; Maughan, TS; Gilson, D; Vernon, C; Syndikus, I; Linch, DC; (2005) Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. CLINICAL ONCOLOGY , 17 (1) 47 - 53.

Howard, PW; Chen, ZZ; Gregson, SJ; Stephenson, M; Klee, S; Hartley, J; ... Thurston, DE; + view all (2005) Design, synthesis and biological evaluation of ZC-423, a novel C2-aryl substituted pyrrolobenzodiazepine PBD) dimer. In: CLINICAL CANCER RESEARCH. (pp. 9015S - 9016S). AMER ASSOC CANCER RESEARCH

Howie, AJ; Pankhurst, T; Sarioglu, S; Turhan, N; Adu, D; (2005) Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int , 67 (3) 987 - 1001. 10.1111/j.1523-1755.2005.00162.x.

J

Jonathan, C-B; (2005) Freezing used to kill cancer cells. The Sunday Times

K

Kelly, CMA; Lee, SM; Steele, JP; (2005) Neoadjuvant chemotherapy for non-small cell lung cancer. In: Andrew, M, (ed.) Key Advances in Lung Cancer. (67 - 74). Aesculapius Medical Press: London, San Franscisco and Sydney.

Kogelberg, H; Tolner, B; Lowdell, M; Qureshi, U; Robson, M; Dearling, JL; ... Chester, KA; + view all (2005) Mechansims of clearance of the antibody-directed enzyme prodrug therapeutic, the mannosylated MFE-CP. In: (Proceedings) NCRI Cancer Conference Proceedings.

Kotecha, M; O'Hare, C; Wells, G; Howard, P; Thurston, D; Mantovani, R; ... Hochhauser, D; + view all (2005) Inhibition of DNA binding of the transcription factor complex NF-Y by a pyrrolobenzodiazepine-polyamide conjugate. In: CLINICAL CANCER RESEARCH. (pp. 9016S - 9016S). AMER ASSOC CANCER RESEARCH

Krause, M; Wohlfarth, J; Georgi, B; Pimentel, N; Dorner, D; Zips, D; ... Baumann, M; + view all (2005) Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY , 81 (10) 751 - 758.

Kristeleit, R; Fong, P; Aherne, GW; de Bono, J; (2005) Histone deacetylase inhibitors: emerging anticancer therapeutic agents? Clinical lung cancer. , 7 Suppl 1

L

Lee, M; Mahroof, S; Pringle, J; Short, SC; Briggs, TWR; Cannon, SR; (2005) Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy. INTERNATIONAL ORTHOPAEDICS , 29 (6) 403 - 405.

Lee, M; Sato, A; Kim, S; Scott, A; Ellington, M; Frazier, W; ... Kiakos, K; + view all (2005) Novel class of duocarmycin analogs: Design, synthesis and biological evaluation of achiral seco-CBI analogs and CC-1065. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. (pp. U344 - U344). AMER CHEMICAL SOC

LePla, RC; Landreau, CAS; Shipman, M; Hartley, JA; Jones, GDD; (2005) Azinomycin inspired bisepoxides: influence of linker structure on in vitro cytotoxicity and DNA interstrand cross-linking. BIOORG MED CHEM LETT , 15 (11) 2861 - 2864. 10.1016/j.bcml.2005.03.091.

Lo, S; Tolner, B; Taanman, JW; Cooper, JM; Gu, M; Hartley, JA; ... Hochhauser, D; + view all (2005) Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. INT J ONCOL , 27 (2) 337 - 344.

M

Macbeth, F; Stephens, R; Hoskin, P; (2005) Radiation dose in spinal cord compression. UNSPECIFIED

Makris, A; (2005) Report on the 9th International conference on primary therapy of early breast cancer. (Breast Cancer Forum , pp. 2 - 6 ).

Makris, A; (2005) Tamoxifen and exemestane:to switch or not to switch? UNSPECIFIED

Makris, A; Hisenbeck, SG; Yee, D; Osborne, KC; Elledge, RM; Harrison, M; ... Chang, JC; + view all (2005) A prospective randomized multicenter gene expression study of docetaxel vs doxorubicin/cyclophosphamide preoperative trial in primary breast cancers. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 14S - 14S).

Marie-Egyptienne, DT; Cerone, MA; Londoño-Vallejo, JA; Autexier, C; (2005) A human-Tetrahymena pseudoknot chimeric telomerase RNA reconstitutes a nonprocessive enzyme in vitro that is defective in telomere elongation. Nucleic Acids Res , 33 (17) 5446 - 5457. 10.1093/nar/gki848.

Martin, C; Ellis, T; McGurk, CJ; Jenkins, TC; Hartley, JA; Waring, MJ; Thurston, DE; (2005) Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: Footprinting and enzyme inhibition studies. BIOCHEMISTRY-US , 44 (11) 4135 - 4147. 10.1021/bi0479813.

Mawdsley, S; Glynne-Jones, R; Grainger, J; Richman, P; Makris, A; Harrison, M; ... Wallace, M; + view all (2005) Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? International Journal of Radiation Oncology Biology Physics , 63 (3) 745 - 752.

McLean, SR; Gana-Weisz, M; Hartzoulakis, B; Frow, R; Whelan, J; Selwood, D; Boshoff, C; (2005) Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val(654)Ala. MOL CANCER THER , 4 (12) 2008 - 2015. 10.1158/1535-7163.MCT-05-0070.

McTiernan, A; Meyer, T; Michelagnoli, MP; Lewis, I; Whelan, JS; (2005) A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatric Blood and Cancer , 46 (3) 345 - 350.

N

Nooij, MA; Whelan, J; Bramwell, VHC; Taminiau, AT; Cannon, S; Hogendoorn, PCW; ... European Osteosarcoma Intergrp,; + view all (2005) Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. EUR J CANCER , 41 (2) 225 - 230. 10.1016/j.ejca.2004.08.026.

O

O'Connell, NM; Saunders, RE; Lee, CA; Perry, DJ; Perkins, SJ; (2005) Structural interpretation of 42 mutations causing factor XI deficiency using homology modeling. J THROMB HAEMOST , 3 (1) 127 - 138.

O'Donnell, P; Diss, TC; Whelan, J; Flanagan, AM; (2005) Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. Skeletal Radiology , 35 (4) 233 - 239.

P

Padhani, AR; Ah-See, ML; Makris, A; (2005) MRI in the detection and management of breast cancer. Expert review of anticancer therapy , 5 (2) 239 - 252.

Padhani, AR; Ah-See, ML; Taylor, NJ; Stirling, JJ; Daley, FM; Richamn, PI; ... Makris, A; + view all (2005) MRI correlates of tumour grade and hypoxia status in human breast cancer. In: Proceedings of the International Society of Magnetic Resonance Medicine.

Parker, LL; Anderson, FM; O'Hare, CC; Lacy, SM; Bingham, JP; Robins, DJ; Hartley, JA; (2005) Synthesis of novel DNA cross-linking antitumour agents based on polyazamacrocycles. BIOORGAN MED CHEM , 13 (7) 2389 - 2395. 10.1016/j.bmc.2005.01.055.

Pedley, RB; El Emir, E; Sharma, SK; Qureshi, U; Dearling, JAB; R, HJ; (2005) Therapeutic effects of the antivascular agent combretastatin A-1 phosphate on orthotopic and subcutaneous colorectal tumours in nude mice. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 943 - ?).

Peleg, M; Steele, R; Thomson, R; Patkar, V; Rose, T; Fox, J; (2005) Open-source publishing of medical knowledge for creation of computer-interpretable guidelines. In: Miksch, S and Hunter, J and Keravnou, E, (eds.) ARTIFICIAL INTELLIGENCE IN MEDICINE, PROCEEDINGS. (pp. 156 - 160). SPRINGER-VERLAG BERLIN

Peltenburg, LT; de Bruin, EC; Meersma, D; Smit, NP; Schrier, PI; Medema, JP; (2005) Expression and function of the apoptosis effector Apaf-1 in melanoma. Cell Death Differ , 12 (6) 678 - 679. 10.1038/sj.cdd.4401630.

Perkins, SJ; Gilbert, HE; Lee, YC; Sun, ZF; P, B; (2005) Relating small angle scattering and analytical ultracentrifugation in multidomain proteins. In: Scott, DJ and Harding, SE and Rowe, AJ, (eds.) Modern Analytical Ultracentrifugation: Techniques and Method. (291 - 319). Royal Society of Chemistry: London,UK.

Pinto, ES; Mensah, R; Meeran, K; Cameron, JD; Murugaesu, N; Bulpitt, CJ; Rajkumar, C; (2005) Peripheral arterial compliance differs between races: comparison among Asian, Afro-Caribbeans, and white Caucasians with type 2 diabetes. Diabetes Care , 28 (2) 496 - ?.

Plummer, ER; Middleton, MR; Jones, C; Olsen, A; Hickson, I; McHugh, P; ... Curtin, NJ; + view all (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. CLIN CANCER RES , 11 (9) 3402 - 3409.

Plummer, R; Middleton, M; Wilson, R; Evans, J; Jones, C; Olson, A; ... Calvert, H; + view all (2005) Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide. In: CLINICAL CANCER RESEARCH. (pp. 9099S - 9099S). AMER ASSOC CANCER RESEARCH

Plummer, R; Middleton, M; Wilson, R; Jones, C; Evans, J; Robson, L; ... Calvert, AH; + view all (2005) First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY , 23 (16) 208S - 208S.

Plummer, R; Vidal, L; Perrett, R; Shaw, H; Pilkington, M; Hanwell, J; ... de Bono, J; + view all (2005) A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors. In: CLINICAL CANCER RESEARCH. (pp. 8990S - 8990S). AMER ASSOC CANCER RESEARCH

Pors, K; Phillips, RM; Hartley, JA; Patterson, LH; (2005) N-oxides of alkylating anthraquinones as hypoxia-targeting prodrugs. In: CLINICAL CANCER RESEARCH. (pp. 9053S - 9053S). AMER ASSOC CANCER RESEARCH

Price, CA; Lingerfelt, BM; Handl, HL; Kiakos, K; Hartley, JA; Lee, M; (2005) Sequence specific recognition of DNA by tailor-made hairpin conjugates of achiral seco-cyclopropaneindoline-2-benzofurancarboxamide and pyrrole-imidazole polyamides. BIOORG MED CHEM LETT , 15 (12) 3151 - 3156. 10.1016/j.bmcl.2005.04.006.

Price, CA; Lingerfelt, BM; Handl, HL; Kiakos, K; Hartley, JA; Lee, M; (2005) Sequence specific recognition of DNA by tailor-made hairpin conjugates of achiral seco-cyclopropaneindoline-2-benzofurancarboxamide and pyrrole-imidazole polyamides. Bioorg Med Chem Lett , 15 (12) 3151 - 3156. 10.1016/j.bmcl.2005.04.006.

Pritchard-Jones, K; Spendlove, I; Wilton, C; Durrant, LG; Whelan, J; Weeden, S; ... Halbert, G; + view all (2005) Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. British Journal of Cancer , 92 (8) 1358 - 1365. 10.1038/sj.bjc.6602500.

R

Rades, D; Stalpers, LJA; Veninga, T; Hoskin, PJ; (2005) Spinal reirradiation after short-course RT for metastatic spinal cord compression. International Journal of Radiation Oncology Biology Physics , 63 (3) 872 - 875.

Rades, D; Stalpers, LJA; Veninga, T; Schulte, R; Hoskin, PJ; Alberti, W; (2005) Effectiveness and toxicity of reirradiation (Re-RT) for metastatic spinal cord compression (MSCC). STRAHLENTHERAPIE UND ONKOLOGIE , 181 (9) 595 - 600.

Rades, D; Stalpers, LJA; Veninga, T; Schulte, R; Hoskin, PJ; Obralic, N; ... Schild, SE; + view all (2005) Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. Journal of Clinical Oncology , 23 (15) 3366 - 3376.

Raja, FA; Bridgewater, JA; (2005) Survival following first line fluorouracil single agent therapy for advanced colarectal cancer in a cancer unit practice in the United Kingdom (UK). In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 274S - 274S). AMER SOC CLINICAL ONCOLOGY

Ravn, P; Thornton, A; Chester, KA; Pedley, B; Davidson, B; Winslet, M; ... Meyer, T; + view all (2005) In situ selection of single chain antibodies by ex vivo perfusion of tumour-bearing human organs with phage display antibody libraries. In: (Proceedings) NCRI Cancer Conference Proceedings.

Robertson, JFR; Come, SE; Jones, SE; Beex, L; Kaufmann, M; Makris, A; ... Rutqvist, LE; + view all (2005) Endocrine treatment options for advanced breast cancer - the role of fulvestrant. EUROPEAN JOURNAL OF CANCER , 41 (3) 346 - 356.

Roos, DE; Turner, SL; O'Brien, PC; Smith, JG; Spry, NA; Burmeister, BH; ... Ball, DL; + view all (2005) Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiotherapy & Oncology , 75 (1) 54 - 63.

Rudd, RM; Gower, NH; Spiro, G; Lee, SM; Eisen, TG; Harper, PG; ... Rankin, EM; + view all (2005) Is the tolerance to MIP Chemotherapy different Between English and Other European Populations? Journal of Clinical Oncology , 23 (25) 6270 - 6271.

Rudd, RM; Gower, NH; Spiro, SG; Eisen, TG; Harper, PG; Littler, JAH; ... Lee, SM; + view all (2005) Gemcitabine plus Carboplatin versus Mitomycin,Ifosfamide, and Cisplatin in patients with stage IIIB orIV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. Journal of Clinical Oncology , 23 (1) 142 - 153. 10.1200/JCO.2005.03.037.

S

Sainz-Pastor, N; Tolner, B; Huhalov, A; Kogelberg, H; Begent, RHJ; Chester, KA; (2005) Expression and purification of recombinant carcinoembryonic antigen frm the yeast Pichia pastoris. In: (Proceedings) NCRI Cancer Conference Proceedings.

Sainz-Pastor, N; Tolner, B; Huhalov, A; Kogelberg, H; Begent, RHJ; Chester, KA; (2005) Expression and purification of recombinant carcinoembryonic antigen from the yeast Pichia pastoris. In: (Proceedings) NCRI Cancer Conference Proceedings.

Sainz-Pastor, N; Tolner, B; Huhalov, A; Kogelberg, H; Lee, YC; Zhu, DL; ... Chester, KA; + view all (2005) Deglycosylation to obtain stable and homogeneous Pichia pastoris-expressed N-A1 domains of carcinoembryonic antigen. International Journal of Biological Macromolecules , 39 (1 -3) 141 - 150.

Sato, A; McNulty, L; Cox, K; Kim, S; Scott, A; Daniell, K; ... Lee, M; + view all (2005) A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J Med Chem , 48 (11) 3903 - 3918. 10.1021/jm050179u.

Sato, A; McNulty, LA; Cox, K; Kim, S; Scott, A; Daniell, K; ... Lee, M; + view all (2005) A novel class of in vivo active anticancer agents: Achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J MED CHEM , 48 (11) 3903 - 3918. 10.1021/jm050179u.

Seddon, BM; Cassoni, AM; Galloway, MJ; Rees, JH; Whelan, JS; (2005) Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: A review of the literature and implications for practice. CLIN ONCOL-UK , 17 (5) 385 - 390. 10.1016/j.clon.2005.03.004.

Seddon, BM; McTiernan, AM; Michelagnoli, MP; Gabbie, S; Daw, S; Whelan, JS; (2005) High-dose ifosfamide in relapsed or progressive Ewing's sarcoma. In: Sarcoma Meeting Stuttgart, June, 2005. Sarcoma 2005; 9(1/2): 108 (P150).

Senis, YA; Atkinson, BT; Pearce, AC; Wonerow, P; Auger, JM; Okkenhaug, K; ... Watson, SP; + view all (2005) Role of the p110 delta PI 3-kinase in integrin and ITAM receptor signalling in platelets. PLATELETS , 16 (3-4) 191 - 202. 10.1080/09537100400016711.

Sharma, SK; Bagshawe, KD; Begent, RH; (2005) Advances in antibody-directed enzyme prodrug therapy. Curr Opin Investig Drugs , 6 (6) 611 - 615.

Sharma, SK; Griffin, N; Mayer, A; Tolner, B; Shahbakhti, H; Chester, KA; Begent, RHJ; (2005) Immunogenicity of a glycosylates antibody-enzyme fusion protien (MFECP1) in a phase I/II clinical study of ADEPT. In: (Proceedings) NCRI Cancer Conference Proceedings.

Sharma, SK; Pedley, RB; Bhatia, J; Boxer, GM; El-Emir, E; Qureshi, U; ... Chester, KA; + view all (2005) Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. CLIN CANCER RES , 11 (2) 814 - 825.

Sharma, SK; Pedley, RB; Meyer, A; Tolner, B; Griffin, N; Green, A; ... and Chester, KA; + view all (2005) Pharmacokinetics and pharmakodynamics of a glycosylated antibody-enzyme fusion protein for ADEPT. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 984 - ?).

Short, S; Bourne, S; Martindale, C; Woodcock, M; Jackson, SP; (2005) DNA damage responses at low radiation doses. Radiation Research , 164 (3) 292 - 302. 10.1667/RR3421.1.

Short, S; Buffa, F; Koritzinsky, M; Wouters, B; Bentzen, SM; (2005) Radiation induced changes in gene expression in human glioma cells. In: Proc 6th Wolfsberg Conference on Molecular Radiation Biology/Oncology.

Short, S; C, B; F, K; M, W; B, B; S, M; (2005) UNSPECIFIED In: (Proceedings) 6th Wolfsberg Conference on Molecular Radiation Biology/Oncology.

Short, S; Hoskin, P; Wong, W; (2005) Ovulation and increased FDG uptake on PET: Potential for a false-positive result. LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA

Sujobert, P; Bardet, V; Cornillet-Lefebvre, P; Hayflick, JS; Prie, N; Verdier, F; ... Bouscary, D; + view all (2005) Essential role for the p110 delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. BLOOD , 106 (3) 1063 - 1066. 10.1128/blood-2004-08-3225.

Sujobert, P; Bardet, V; Cornillet-Lefebvre, P; Hayflick, JS; Prie, N; Verdier, F; ... Bouscary, D; + view all (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood , 106 (3) 1063 - 1066. 10.1182/blood-2004-08-3225.

T

Taherbhai, Z; Bailey, S; Sutterfield, A; Buchmueller, K; Nguyen, B; Kotecha, M; ... Lee, M; + view all (2005) ZT-65B, a hairpin polyamide that binds to the inverted CCAAT box (ICB) site of the human multidrug resistant (MDR1) gene: Design, DNA binding, and biological studies. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. (pp. U542 - U543). AMER CHEMICAL SOC

Taylor, NJ; Ah-See, ML; Stirling, JJ; d'Arcy, JA; Collins, DJ; Walker-Samuel, S; ... Padhani, AR; + view all (2005) Pre-and post-chemotherapy comparisons of calculated rBV and rBF with signal intensity drop on T2* dynamic contrast-enhanced MRI of breast cancers. In: Proceedings of the the International Society of Magnetic Resonance Medicine. (pp. 91 - 91).

Thomas, MJ; Smith, A; Head, DH; Milne, L; Nicholls, A; Pearce, W; ... Westwick, J; + view all (2005) Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. EUR J IMMUNOL , 35 (4) 1283 - 1291. 10.1002/eji.200425634.

Thomas, MJ; Smith, A; Head, DH; Milne, L; Nicholls, A; Pearce, W; ... Westwick, J; + view all (2005) Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. EUR J IMMUNOL , 35 (4) 1283 - 1291. 10.1002/eji.200425634.

Thomson, A; Mayne, N; Bamford, A; Daw, S; Whelan, J; Michelagnoli, M; (2005) Acute anthracycline-induced cardiotoxicity in children and adolescents treated for bone cancer. In: SIOP XXXVI Meeting, Vancouver, Canada, Nov 2005.

Tolner, B; Taylorson, CJ; Kogelberg, H; Huhalov, S; Robson, L; Begent, RHJ; Chester, KA; (2005) A humanized ADEPT system using mutated human pancreatic ribonuclease. In: (Proceedings) NCRI Cancer Conference Proceedings.

Toth, JL; Trzupek, JD; Flores, LV; Kiakos, K; Hartley, JA; Pennington, WT; Lee, M; (2005) A novel achiral seco-amino-cyclopropylindoline (CI) analog of CC-1065 and the duocarmycins: design, synthesis and biological studies. Med Chem , 1 (1) 13 - 19.

V

Valle, JW; Dangoor, A; Beech, J; Lee, SM; Scarffe, JH; Swindell, R; Ranson, M; (2005) Treatment of inoperable hepatocellular carcinoma (HCC) with pegylated liposomal doxorubicin (PLD) – results of a phase II study. British Journal of Cancer , 92 (4) 628 - 630.

Vanhaesebroeck, B; Ali, K; Bilancio, A; Geering, B; Foukas, LC; (2005) Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci , 30 (4) 194 - 204. 10.1016/j.tibs.2005.02.008.

UNSPECIFIED (Ed). (2005) Novel implantable delivery system increases maximum tolerable doses of paclitaxel in mice. [Whole issue]. Proc Amer Assoc Cancer Res , 46

Venables, K; Miles, EA; Hoskin, PJ; Aird, EGA; (2005) Verification films: A study of the daily and weekly reproducibility of breast patient set-up in the START trial. Clinical Oncology , 17 (5) 337 - 342.

Vidal, L; Leslie, M; Sludden, J; Griffin, MG; Plummer, R; Judson, I; ... Boddy, AV; + view all (2005) A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98. JOURNAL OF CLINICAL ONCOLOGY , 23 (16) 209S - 209S.

Vigor, K; Lee, YC; Farrell, D; Huhalov, S; Robson, L; Begent, RHJ; Chester, KA; (2005) Antibody-nanoparticle complexation for hyperthermic treatment of tumours. In: (Proceedings) NCRI Cancer Conference Proceedings.

Violet, JA; Dearling, JLJ; Marley, SJ; Green, AJ; Begent, RHJ; and, PRB; (2005) Dose fractionation reduces efficacy of radioimmunotherapy without decreasing toxicity. In: European Journal of Nuclear Medicine and Molecular Imaging. (pp. 207 - ?).

W

Westbury, C; Yarnold, J; (2005) Can a 'low risk' subgroup be identified in whom radiotherapy can safely be omitted after breast conservation surgery? In: MD, RL, (ed.) The effective management of breast cancer. (? - ?).

Whelan, JS; (2005) Osteosarcoma. In: Eden, OB and Barr, R and Bleyer, A and Whiteson, M, (eds.) Cancer and the Adolescent. Blackwell Publishing: Oxford.

Whelan, JS; McTiernan, AM; Weston, C; Ahrens, S; Grimer, R; Lewis, I; ... Craft, A; + view all (2005) Differences in survival between Study Groups detected in an international randomised study: analysis of Eicess 92. In: Sarcoma Meeting Stuttgart, June, 2005. Sarcoma 2005; 9(1/2): 115 (P177).

This list was generated on Sun Sep 28 03:45:23 2014 BST.